Hyo-Eun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hyo-Eun Lee has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ji-Hoon Lee
Department of Aquatic Life Medicine, Kunsan National University, Gunsan, Republic of Korea
3 shared publications - Ga Won Kim2 shared publications
- Joo-Won Hong2 shared publications
- Jung Soo Seo2 shared publications
- Mun-Gyeong Kwon
Aquatic Disease Control Division, National Fishery Products Quality Management Service, Busan 46083, Republic of Korea
2 shared publications - Mun-Gyeong Kwon
Aquatic Disease Control Division, National Fishery Products Quality Management Service, Busan 46083, Korea
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by The Korean Society of Fisheries and Aquatic Science in Fisheries and Aquatic Sciences
- Vol. 29 (9) , 612-621
Tissue recovery and amoxicillin residue depletion at alternative injection sites in olive flounder (Paralichthys olivaceus)
Fisheries and Aquatic Sciences
- 30 September 2026
- Published by The Korean Society of Fisheries and Aquatic Science in Fisheries and Aquatic Sciences
- Vol. 29 (9) , 612-621
Open AccessTissue recovery and amoxicillin residue depletion at alternative injection sites in olive flounder (Paralichthys olivaceus)
Fisheries and Aquatic Sciences
- Open Access
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Site and Temperature Dependent Pharmacokinetics, Pharmacodynamics, and Withdrawal Time of Ceftiofur in Olive Flounder (Paralichthys olivaceus)
This study aimed to identify alternative intramuscular injection sites for ceftiofur in olive flounder (Paralichthys olivaceus) that maintain therapeutic efficacy and residue compliance while mitigating injection-site lesions in the edible dorsal fillet, which can reduce consumer acceptance despite short regulatory withdrawal periods. Following a single 10 mg/kg dose at four sites (dorsal, tail, cheek, pectoral fin) under two temperatures (23 °C, 13 °C), HPLC–MS/MS quantified exposure and residue depletion; PK/PD indices and withdrawal times were integrated with histopathology. %T>MIC exceeded β-lactam thresholds in most conditions, with the exception of pectoral fin at 13 °C (32.7% assuming MIC = 1 µg/mL). Dorsal injection at 23 °C met the 7-day withdrawal period, whereas non-dorsal sites exceeded this limit at the 99% tolerance level. Histopathology revealed lesions persisting to 168 h post-injection at all sites, underscoring marketability concerns for edible fillet. Collectively, tail muscle demonstrated relatively stable pharmacokinetics across temperatures and may represent a viable alternative injection site; however, an extended withdrawal period beyond the currently approved 7 days would be required for regulatory compliance at 23 °C. Dorsal injection provides the best balance of efficacy and regulatory compliance. These findings support site-specific dosing guidance to optimize outcomes and consumer acceptance.
- 15 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSite and Temperature Dependent Pharmacokinetics, Pharmacodynamics, and Withdrawal Time of Ceftiofur in Olive Flounder (Paralichthys olivaceus)
This study aimed to identify alternative intramuscular injection sites for ceftiofur in olive flounder (Paralichthys olivaceus) that maintain therapeutic efficacy and residue compliance while mitigating injection-site lesions in the edible dorsal fillet, which can reduce consumer acceptance despite short regulatory withdrawal periods. Following a single 10 mg/kg dose at four sites (dorsal, tail, cheek, pectoral fin) under two temperatures (23 °C, 13 °C), HPLC–MS/MS quantified exposure and residue depletion; PK/PD indices and withdrawal times were integrated with histopathology. %T>MIC exceeded β-lactam thresholds in most conditions, with the exception of pectoral fin at 13 °C (32.7% assuming MIC = 1 µg/mL). Dorsal injection at 23 °C met the 7-day withdrawal period, whereas non-dorsal sites exceeded this limit at the 99% tolerance level. Histopathology revealed lesions persisting to 168 h post-injection at all sites, underscoring marketability concerns for edible fillet. Collectively, tail muscle demonstrated relatively stable pharmacokinetics across temperatures and may represent a viable alternative injection site; however, an extended withdrawal period beyond the currently approved 7 days would be required for regulatory compliance at 23 °C. Dorsal injection provides the best balance of efficacy and regulatory compliance. These findings support site-specific dosing guidance to optimize outcomes and consumer acceptance.
- Open Access
- 5 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1153
Influence of Intramuscular Injection Sites on Pharmacokinetics of Amoxicillin in Olive Flounder (Paralichthys olivaceus) and Its Implication for Antibacterial Efficacy
This study aimed to investigate the effects of different injection sites, including dorsal, cheek, and pectoral fin muscles, on the pharmacological properties of amoxicillin (AMOX) in olive flounder (Paralichthys olivaceus) after a single intramuscular (IM) injection of 40 mg/kg. The AMOX concentration was measured using high-performance liquid chromatography-tandem mass spectrometry, followed by a non-compartmental model analysis. The peak serum concentrations (Cmax) achieved 3 h after dorsal, cheek, and pectoral fin IM injections were 202.79, 203.96, and 229.59 μg/mL, respectively. The area under the concentration-time curve (AUC) was 1697.23, 2006.71, and 1846.61 µg/mL·h, respectively. The terminal half-life (t1/2λZ) was prolonged for cheek and pectoral fin IM injections (10.12 and 10.33 h, respectively) compared to dorsal IM injection (8.89 h). In the pharmacokinetic-pharmacodynamic analysis, a higher T > minimum inhibitory concentration (MIC) and AUC/MIC values were observed after AMOX was injected into the cheek and pectoral fin muscles compared to the dorsal muscle. Muscle residue depletion was below the maximum residue level from day 7 after IM injection at all three sites. These findings suggest that the cheek and pectoral fin sites provide advantages regarding systemic drug exposure and prolonged action compared with the dorsal site.
- 5 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1153
Open AccessInfluence of Intramuscular Injection Sites on Pharmacokinetics of Amoxicillin in Olive Flounder (Paralichthys olivaceus) and Its Implication for Antibacterial Efficacy
This study aimed to investigate the effects of different injection sites, including dorsal, cheek, and pectoral fin muscles, on the pharmacological properties of amoxicillin (AMOX) in olive flounder (Paralichthys olivaceus) after a single intramuscular (IM) injection of 40 mg/kg. The AMOX concentration was measured using high-performance liquid chromatography-tandem mass spectrometry, followed by a non-compartmental model analysis. The peak serum concentrations (Cmax) achieved 3 h after dorsal, cheek, and pectoral fin IM injections were 202.79, 203.96, and 229.59 μg/mL, respectively. The area under the concentration-time curve (AUC) was 1697.23, 2006.71, and 1846.61 µg/mL·h, respectively. The terminal half-life (t1/2λZ) was prolonged for cheek and pectoral fin IM injections (10.12 and 10.33 h, respectively) compared to dorsal IM injection (8.89 h). In the pharmacokinetic-pharmacodynamic analysis, a higher T > minimum inhibitory concentration (MIC) and AUC/MIC values were observed after AMOX was injected into the cheek and pectoral fin muscles compared to the dorsal muscle. Muscle residue depletion was below the maximum residue level from day 7 after IM injection at all three sites. These findings suggest that the cheek and pectoral fin sites provide advantages regarding systemic drug exposure and prolonged action compared with the dorsal site.
- Open Access
First Report of Enterocytozoon hepatopenaei Infection in Giant Freshwater Prawn (Macrobrachium rosenbergii de Man) Cultured in the Republic of Korea
In the Republic of Korea, Enterocytozoon hepatopenaei (EHP) was first isolated from Pacific whiteleg shrimp in April 2020; however, there are no existing reports of EHP infection in other shrimp or prawns. Here, we aimed to investigate EHP infection and its prevalence in giant freshwater prawn farms in the Republic of Korea. We tested prawns from 22 farms for EHP infection, and samples from eight farms showed positive EHP infection results in 2021. In EHP-infected prawn farms, the prevalence ranged from 4.9% to 18.2%. The prevalence of EHP infection in the Republic of Korea, derived from the prevalence in prawn farms, was estimated to be 0.8% in 2021. The proliferation of EHP was observed within the hepatopancreatic epithelial cells of prawns using H&E and Giemsa staining. Mature EHP was observed in the sinus between epithelial cells of the digestive tubules. Phylogenetic analysis revealed a clade distinct from the previously reported EHP in Pacific whiteleg shrimps. This is the first report of EHP infection in a giant freshwater prawn in the Republic of Korea, where the prevalence of EHP infection is not high, but it is recognized as an emerging disease that requires periodic monitoring and quarantine management in giant freshwater prawns.
Open AccessFirst Report of Enterocytozoon hepatopenaei Infection in Giant Freshwater Prawn (Macrobrachium rosenbergii de Man) Cultured in the Republic of Korea
In the Republic of Korea, Enterocytozoon hepatopenaei (EHP) was first isolated from Pacific whiteleg shrimp in April 2020; however, there are no existing reports of EHP infection in other shrimp or prawns. Here, we aimed to investigate EHP infection and its prevalence in giant freshwater prawn farms in the Republic of Korea. We tested prawns from 22 farms for EHP infection, and samples from eight farms showed positive EHP infection results in 2021. In EHP-infected prawn farms, the prevalence ranged from 4.9% to 18.2%. The prevalence of EHP infection in the Republic of Korea, derived from the prevalence in prawn farms, was estimated to be 0.8% in 2021. The proliferation of EHP was observed within the hepatopancreatic epithelial cells of prawns using H&E and Giemsa staining. Mature EHP was observed in the sinus between epithelial cells of the digestive tubules. Phylogenetic analysis revealed a clade distinct from the previously reported EHP in Pacific whiteleg shrimps. This is the first report of EHP infection in a giant freshwater prawn in the Republic of Korea, where the prevalence of EHP infection is not high, but it is recognized as an emerging disease that requires periodic monitoring and quarantine management in giant freshwater prawns.
- Open Access
- 1 April 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 182 (Supplement) , 88.12
Preventive effects of Paeonol on cisplatin induced nephrotoxicity in mice (88.12)
Paeonol, a major phenolic compound of Moutan Cortex, was known that to have antioxidant and anti-inflammatory activities. Cisplatin is a chemotherapeutic agent, however, its nephrotoxicity limits the use of this drug. In the present research, we examines whether paeonol has protective effects on cisplatin induced acute renal failure in mice. Animals were given 20mg/kg of paeonol intraperitoneally for 3 days. At 4 days, all groups of mice received a single dose of cisplatin at 30mg/kg intraperitoneally. Paeonol treated group marked attenuation in serum creatine, BUN, and survival. Paeonol treated group had a significantly reduced the levels of proinflammatory cytokines when compared to the control group. These results demonstrated that Paeonol pre-administration can prevent the renal toxic effects of cisplatin.
- 1 April 2009
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 182 (Supplement) , 88.12
Open AccessPreventive effects of Paeonol on cisplatin induced nephrotoxicity in mice (88.12)
Paeonol, a major phenolic compound of Moutan Cortex, was known that to have antioxidant and anti-inflammatory activities. Cisplatin is a chemotherapeutic agent, however, its nephrotoxicity limits the use of this drug. In the present research, we examines whether paeonol has protective effects on cisplatin induced acute renal failure in mice. Animals were given 20mg/kg of paeonol intraperitoneally for 3 days. At 4 days, all groups of mice received a single dose of cisplatin at 30mg/kg intraperitoneally. Paeonol treated group marked attenuation in serum creatine, BUN, and survival. Paeonol treated group had a significantly reduced the levels of proinflammatory cytokines when compared to the control group. These results demonstrated that Paeonol pre-administration can prevent the renal toxic effects of cisplatin.